The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib (VBMCP/VBAD/B) in patients aged 65 years or younger with multiple myeloma. The primary endpoint was complete response (CR) rate postinduction and post-autologous stem cell transplantation (ASCT). Three hundred eighty-six patients were allocated to VTD (130), TD (127), or VBMCP/VBAD/B (129). The CR rate was significantly higher with VTD than with TD (35% vs 14%, P = .001) or with VBMCP/VBAD/B (35% vs 21%, P = .01). The median progression-free survival (PFS) was significantly longer with VTD (56.2 vs 28.2 vs 35.5 months, P = .01). In an intention-to-treat analysis, the post-ASCT CR rate was higher with VTD than with TD (46% vs 24%, P = .004) or with VBMCP/VBAD/B (46% vs 38%, P = .1). Patients with high-risk cytogenetics had a shorter PFS and overall survival in the overall series and in all treatment groups. In conclusion, VTD resulted in a higher pre- and posttransplantation CR rate and in a significantly longer PFS although it was not able to overcome the poor prognosis of high-risk cytogenetics. Our results support the use of VTD as a highly effective induction regimen prior to ASCT. The study was registered with http://www.clinicaltrials.gov (NCT00461747) and Eudra CT (no. 2005-001110-41).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2012-02-408922 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Veratridine Induces Vasorelaxation in Mouse Cecocolic Mesenteric Arteries.
Toxins (Basel)
December 2024
Univ. Angers, INSERM, CNRS, MITOVASC, Equipe CarME, SFR ICAT, 49000 Angers, France.
The vegetal alkaloid toxin veratridine (VTD) is a selective voltage-gated Na (Na) channel activator, widely used as a pharmacological tool in vascular physiology. We have previously shown that Na channels, expressed in arteries, contribute to vascular tone in mouse mesenteric arteries (MAs). Here, we aimed to better characterize the mechanisms of action of VTD using mouse cecocolic arteries (CAs), a model of resistance artery.
View Article and Find Full Text PDFThe evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective cohort study of real-world clinical practice.
EJHaem
December 2024
Johnson & Johnson Innovative Medicine Lisbon Portugal.
Objectives: To characterize variations in real-world treatment patterns in multiple myeloma (MM) in Portugal over a 5-year period.
Methods: A retrospective cohort multicenter study using secondary data of national hospital drug consumption database from 11 Portuguese public hospitals between 2017 and 2022.
Results: Number of MM-treated patients increased 53% over 5 years (from 825 to 1266 patients).
Article Synopsis
- Advances in colorectal cancer (CRC) treatment face challenges due to fast tumor spread and screening issues, especially for early-onset CRC, highlighting the need for better therapies.
- The Rictor-mTORC2-AKT pathway is critical in promoting metastasis, and selective inhibitors targeting mTORC2, like Veratridine (VTD), show promise in reducing tumor growth and metastasis.
- VTD acts by destabilizing Rictor, leading to decreased cancer stem cell populations and aggressive tumor behaviors in CRC, offering a new potential approach to treatment.
A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults.
Clin Transl Sci
November 2024
Alpine Immune Sciences, a Vertex Company, Seattle, Washington, USA.
Therapeutic agents targeting the tumor necrosis factor (TNF) superfamily cytokines B-cell activating factor (BAFF, BLyS) and/or A PRoliferation Inducing Ligand (APRIL) have demonstrated clinical effectiveness in multiple autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis, and immunoglobulin A nephropathy (IgAN). However, their clinical utility can often be limited by incomplete and/or prolonged times to clinical response and inconvenient dosing regimens, which may be improved by more potent dual inhibition of both cytokines. Povetacicept (ALPN-303; TACI vTD-Fc) is a crystallizable fragment (Fc) fusion protein of an engineered transmembrane activator and CAML interactor (TACI) domain which mediates more potent inhibitory activity than wild-type TACI-Fc or BAFF- or APRIL-specific antibodies and demonstrates superior pharmacokinetic and pharmacodynamic activity in multiple preclinical disease models.
View Article and Find Full Text PDFFirst-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study.
Cancers (Basel)
September 2024
Institute of Clinical Physiology (IFC-CNR), Section of Rome, 00185 Rome, Italy.
Article Synopsis
- This study examined the effects of D-VTd induction therapy on recovery after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (NDMM).
- Sixty patients received D-VTd while 80 others received VTd as a control, with results showing that D-VTd led to a slightly longer time for neutrophil and platelet recovery.
- Despite delayed engraftment in the D-VTd group and a higher incidence of febrile neutropenia, the study concluded that D-VTd does not negatively affect overall transplant safety outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!